Imedex

Dr. Richard MacDermott provides a written discussion for the practicing clinician outlining key learning points from the Great Debates and Updates in IBD meeting held this past March in New York. Dr. MacDermott’s comments highlight the points and counterpoints of the debate issues and the “Take Home Messages” from the didactic lectures discussing current practice guidelines and management strategies for pediatric and adult patients with IBD.

Multiple novel targets with curative potential have been identified in multiple myeloma in recent years and agents directed against these targets have demonstrated encouraging anti-tumor activities and gained prominence in the treatment of relapsed disease. In this online monograph, Dr. Sagar Lonial discusses some of the new targets and agents in development and provides an expert perspective on how these agents will further improve clinical outcomes for patients with relapsed multiple myeloma.

This webcast is comprised of presentations from the Annual NOCR meeting held in Las Vegas, Nevada in February of 2012. Topics include hematologic malignancy updates as well as a very thorough overview of multiple solid tumor cancers and current and emerging standards. An outstanding group of faculty presented at this meeting.

Recent research has uncovered many potential biomarkers and genetic mutations, which may be able to predict patients' outcomes and response to specific agents. Use of these molecular biomarkers to guide and personalize treatment choices is a major and growing area of interest in the field of NSCLC research. Please join Drs Langer, Tsao, and Gitlitz as they review the latest findings on emerging targeted agents and accompanying diagnostic tests in the field of non-small cell lung cancer.

Advances in our understanding of the mechanisms of breast cancer have resulted in novel therapies and improvements in aspects of disease management, but have also given rise to new challenges and debates. Given the rapid pace of research in this field, it is essential for clinicians to stay informed of the latest findings and their potential impact on clinical practice. There is thus a strong need for dissemination and discussion of cutting-edge clinical data on breast cancer.

In this webcast, Confronting the Challenges of Tuberous Sclerosis Complex:Strategies for Treatment and Management of Associated Angiomyolipomas, a symposium during the 27th Annual EAU Congress, thought leaders address the current educational needs of specialists within the community and academic settings with knowledge of recently released clinical trial data and evidence-based medical recommendations. Combining clinical cases, lectures, and expert faculty discussions, this symposium will begin to bridge the practice gaps of clinicians regarding the multidisciplinary approach involving surgery and medical therapy as mainstays of treatment for patients with TSC, in addition to emerging targeted biologic therapies showing promise in improving patient outcomes.

Join Dr Charles S. Fuchs as he highlights data presented during the symposium Incorporation of Critical Advances in the Management of Upper GI Cancer. Dr Fuchs reviews recent progress and ongoing clinical trials over the wide spectrum of upper GI malignancies including gastric, pancreatic neuroendorcine, hepatocellular and pancreatic cancers.

Vascular endothelial growth factor (VEGF) is a key protein involved in tumor angiogenesis and consequently a rational therapeutic target in colorectal cancer. In an effort to improve upon the first-generation of angiogenesis inhibitors, clinical investigators embarked on a search for other effective agents for the treatment of metastatic colorectal cancer giving way to the second-generation angiogensis inhibitors. Join Drs. Axel Grothey and John Marshall as they discuss the development of these agents and role through the continuum of care of angiogeneisis inhibitors in the field of mCRC.

Preclinical and clinical investigations provide a strong rationale for the use of angiogenesis inhibitors in ovarian primary peritoneal/fallopian tube cancer, and a large variety of angiogenesis inhibitors are in late stages of development. Drs. Thomas Herzog and Robert Burger discuss VEGF and VEGFR inhibitors including emerging data from clinical trails, management of toxicities and the future direction of this field.

In this webcast, Optimizing Diagnostics in IBD: Tools for the Practicing Gastroenterologist, a symposium during the 2011 Advances in Inflammatory Bowel Diseases, Crohn’s & Colitis Foundation’s Clinical & Research Conference, three thought leaders discuss the latest practical application tools to aid in the diagnosis of patients with inflammatory bowel diseases. Tools include endoscopy, yet focus more heavily on non-invasive methods such as CR and MR enterography as well as recent data and applicability of serologic, genetic and immunologic markers.